Monday after hours

Shares of Netlist Inc. (Nasdaq: NLST) fell $0.86, or 14.4%, to $5.11 in after-hours trading Monday after the memory subsystems manufacturer issued a lower-than-expected revised first-quarter guidance. Irvine, Calif.-based Netlist said it now expects to report earnings per share of $0.02 to $0.03 per share on revenue of $37 million to $38 million. The firm had previously issued guidance of $0.07 to $0.08 per share on revenue of $40 million to $42 million. Three analysts polled by Thomson First Call were expecting earnings per share of $0.08 on revenue of $41.2 million for the quarter ended March 31. Netlist CEO Chuck Hong cited operating expenses and decreased customer demand for the revised guidance.

Electronics components distributor Nu Horizons Electronics Corp.’s (Nasdaq: NUHC) stock dipped late Monday when the company reported after-hours that it had received a subpoena from the Securities and Exchange Commission (SEC). According to a written statement issued by Melville, N.Y.-based Nu Horizons, the SEC is requiring the company to produce documents related to its business relationship with Vitesse Semiconductor Corp. Both Nu Horizons and subsidiary Titan Logistics Corp. are distributors of Vitesse products. Titan Logistics also received a subpoena from the SEC. The firms said they are cooperating fully with the federal agency. Shares of Nu Horizons Electronics Corp. were down $0.14, or 1.2%, to $11.53 in after-hours trading.

InsWeb Corp.’s (Nasdaq: INSW) stock soared by more than half its value, or $1.73, to $5.04 in after-hours trading Monday after the company announced it had turned a profit for the first time. The Sacramento, Calif-based online insurer posted net income of $400,000, or $0.10 per share, on revenue of $8.1 million for the first quarter ended March 31, versus a net loss of $1.7 million, or $0.41 per share, on revenue of $7.7 million a year earlier. Separately, InsWeb also announced the closure of its term life agency as the last stage in the company's plan to concentrate solely on lead generation opportunities. InsWeb said it will continue to offer term life products to consumers visiting its online insurance marketplace through a lead referral model, which the company believes is more profitable and offers a more scalable opportunity.

YM BioSciences’ (AMEX: YMI) stock gained $0.12, or 7.3%, to $1.76, after the Mississaugua, Ontario-based oncology firm said late Monday that its partner Daiichi Sankyo has received the green light for a Phase I trial of nimotuzumam, a tumor treatment in Japan. Nimotuzumab is already approved in India, China, Cuba, Argentina and Colombia for nasopharyngeal and/or head and neck cancer, depending on the country.